The year 2012 has seen relevant changes inPolish pharmaceutical legislation and drugreimbursement, among others limiting thereimbursement solely to indications stated in theSummaries of Product Characteristics (SPCs). Adiscrepancy with expert recommendationsbecame apparent. The aim of the study was toanalyze the concordance between up-to-date recommendations of exert bodies regarding the treatment of urticaria, scientific evidence for the effectiveness of the recommended drugs and SPCs in force in Poland. Material and methods: The analysis of Polish and international expert bodies for the treatment of urticaria published from the year 2000, along with the SPCs and clinical trials of efficacy of recommended drugs. Results: The analyses included altogether 10 published recommendations of expert bodies, 204 Summaries of Product Characteristics, 387 published results of studies on drug efficacy and 5 other legal acts. Of drugs recommended by the experts, 194 were authorized in Poland for urticaria treatment, including 158 oral preparations SGAH containing 7 active substances (bilastine, cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, rupatadine), 29 oral preparations of AH I, 4 preparations of systemic glucocorticosteroids, 2 topical glucocorticosteroid preparations and one combined preparation of human immunoglobulin with histamine. Conclusions: Considerable d ; iscrepancies exist between expert recommendations for the treatment of urticaria, the licensed use of drugs as defined in Summaries of Product Characteristics and the scientific evidence for their effectiveness.
farmacja ; farmakologia ; dermatologia
Mar 20, 2023
Mar 13, 2014
11
0
http://dl.cm-uj.krakow.pl:8080/publication/3660
Edition name | Date |
---|---|
ZB-120305 | Mar 20, 2023 |
Plichta, Danuta
Kordus, Katarzyna.
Kordus, Katarzyna
Podolec-Rubiś, Magdalena
Zorkun, Cafer Sadik
Podolec-Szczepara, Natalia Małgorzata
Grudzień, Agata